Amgen's outlook is buoyed by Horizon's addition and increase...
Amgen's outlook is buoyed by Horizon's addition and increased global sales volume. The company is set to report initial human trial data for AMG786, an experimental oral obesity drug, and mid-stage trial results for MariTide, its lead injectable weight loss candidate, this year.
Amgen Quarterly Profit Rises 15% as Horizon Deal Boosts Results
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3224Followers
0Following
7991Visitors
Follow